Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, engages in developing and marketing human medicines. It engages in developing a pipeline of clinical candidates in the areas of gastrointestinal diseases, cardiovascular diseases, pain, and inflammation. The company's operationally independent subsidiary, Microbia Inc., engages in developing and commercializing bioprocesses for use in pharmaceuticals, foods, and specialty and industrial chemicals. Ironwood Pharmaceuticals, Inc. was formerly known as Microbia, Inc. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.
VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in developing innovative treatments for severe rare diseases with significant unmet medical needs. Its primary product candidate, Apraglutide, is a long-acting synthetic analog of glucagon-like peptide-2 (GLP-2) designed to enhance the intestine's ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support. VectivBio aims to deliver transformational therapies that significantly improve the lives of patients and their families, rather than offering only incremental benefits over existing treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.